Clinical

The meta-analysis of 17 studies found that frailty was strongly associated with cognitive impairment in CKD, highlighting the need for further research to determine a causal relationship.

Oral zasocitinib delivered skin clearance once limited to injectable biologics in phase 3 psoriasis trials, including hard-to-treat sites.

Early remdesivir treatment was associated with lower graft loss and cardiovascular events in kidney transplant recipients, noted Nitipong Permpalung, MD, MPH.

A recent study found semaglutide more than doubled the likelihood of MASH resolution, but it did not significantly improve fibrosis.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

New cancer drugs reached patients fastest, but overall access timelines remained lengthy across the US, France, Germany, and Switzerland.

East Asian patients with generalized myasthenia gravis (gMG) saw meaningful nipocalimab benefits in a Vivacity-MG3 subgroup analysis.

Anti-VEGF has maxed out in diabetic macular edema (DME), but Ang-2 and Wnt pathway approaches could target disease differently, said John Kitchens, MD.

Polygenic risk scores show promise for idiopathic pulmonary fibrosis (IPF), though clinical implementation challenges remain, said David Zhang, MD.

The autoinjector delivers subcutaneous furosemide with IV-equivalent exposure in under 10 seconds for adults with heart failure or CKD-related edema.

June 2026 brought 5 FDA firsts across infectious disease, oncology, and rare disease, expanding treatment options and addressing unmet patient needs.

This segment explores how ESR1 mutation testing may be integrated into clinical workflows for hormone receptor–positive, HER2-negative metastatic breast cancer.

Noureddin framed MASH as one that should not be viewed in isolation by hepatologists or any other specialist, but rather understood as part of a broader cardio-liver-renal metabolic syndrome that demands comprehensive, multidisciplinary management, noting that even lean individuals with elevated visceral fat and insulin resistance can develop MASLD, and that the risk increases substantially with higher BMI and the presence of type 2 diabetes, which is strongly associated with both higher MASLD prevalence and greater rates of advanced fibrosis and cirrhosis.

This segment explores practical considerations for implementing ESR1 mutation testing in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on testing strategy, frequency, and system-level constraints.

Nadege Gunn examined the stark economic contrast between the cost of early pharmacologic intervention in MASH and the astronomical healthcare utilization associated with late-stage liver disease, arguing that the cost of allowing MASH to progress unchecked to the point of hepatic decompensation, liver transplantation, or hepatocellular carcinoma far exceeds the investment required to treat the disease earlier with therapies capable of reversing fibrosis and resolving MASH before those devastating endpoints are reached.

Coverage from the Institute for Value-Based Medicine session in Dallas, Texas, held May 21,2026.

Use of automated insulin delivery technology improves a Healthcare Effectiveness Data and Information Set quality measure in individuals with type 2 diabetes.

Christina Poh described the early phase efficacy data for golcadomide as highly impressive, noting that the high overall response rates and durability of responses a very promising signal that she expects will translate into a meaningful role for this first-in-class oral CELMoD agent in the relapsed or refractory follicular lymphoma treatment landscape in the near future.

Alireza Atri introduces mild behavioral impairment as an early-emerging framework for behavioral changes preceding formal dementia diagnosis.

Christina Poh discussed how the trial data reporting a PFS benefit of 88.9% versus 66.7% at 5 years and an OS advantage for IFRT plus rituximab maintenance in stage III follicular lymphoma does not entirely overturn the conventional view of radiation as a primarily early-stage tool, but does meaningfully challenge the assumption that radiotherapy has no role in advanced-stage disease while noting that additional studies are needed to confirm these findings and to evaluate radiation's role in combination with systemic therapies beyond rituximab.

Kavita Nair leads the discussion on defining Alzheimer's disease agitation.

Eplontersen added to standard of care did not significantly reduce cardiovascular death and recurrent events, a study finds.

David Zhang, MD, discusses the limitations of polygenic risk scores and remaining barriers to their clinical use in idiopathic pulmonary fibrosis.

FDA approves zidesamtinib for ROS1-positive NSCLC after prior TKIs, offering a new option for resistant and CNS-active disease.

David Zhang, MD, discusses how real-world EHR and biobank data could advance polygenic risk scores for IPF diagnosis and risk prediction.